Goldman Sachs Group Inc. bought a new stake in RA PHARMCTL INC (NASDAQ:RARX) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 68,352 shares of the company’s stock, valued at approximately $1,455,000. Goldman Sachs Group Inc. owned 0.30% of RA PHARMCTL INC as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. TIAA CREF Investment Management LLC increased its position in shares of RA PHARMCTL INC by 97.0% in the first quarter. TIAA CREF Investment Management LLC now owns 7,837 shares of the company’s stock valued at $167,000 after buying an additional 3,859 shares during the last quarter. American International Group Inc. bought a new stake in RA PHARMCTL INC during the first quarter valued at $102,000. Geode Capital Management LLC boosted its stake in RA PHARMCTL INC by 8.5% in the first quarter. Geode Capital Management LLC now owns 70,863 shares of the company’s stock valued at $1,508,000 after buying an additional 5,522 shares during the period. Wells Fargo & Company MN boosted its stake in RA PHARMCTL INC by 151.8% in the first quarter. Wells Fargo & Company MN now owns 9,455 shares of the company’s stock valued at $202,000 after buying an additional 5,700 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in RA PHARMCTL INC by 77.4% in the first quarter. Bank of New York Mellon Corp now owns 24,051 shares of the company’s stock valued at $512,000 after buying an additional 10,493 shares during the period. 61.77% of the stock is currently owned by institutional investors.
Shares of RA PHARMCTL INC (RARX) opened at 15.11 on Friday. The stock’s 50 day moving average is $15.50 and its 200-day moving average is $20.28. RA PHARMCTL INC has a one year low of $12.05 and a one year high of $27.84. The company’s market cap is $341.62 million.
Several research firms recently weighed in on RARX. Jefferies Group LLC reiterated a “buy” rating and issued a $25.00 price target on shares of RA PHARMCTL INC in a report on Friday, July 14th. Zacks Investment Research cut shares of RA PHARMCTL INC from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $27.00.
In related news, major shareholder Bioventures Ltd Novartis sold 5,353 shares of the firm’s stock in a transaction dated Friday, May 26th. The stock was sold at an average price of $25.14, for a total transaction of $134,574.42. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In the last ninety days, insiders have sold 157,246 shares of company stock worth $3,612,718. 14.50% of the stock is owned by corporate insiders.
RA PHARMCTL INC Company Profile
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
What are top analysts saying about RA PHARMCTL INC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for RA PHARMCTL INC and related companies.